Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3678-5
Abstract: PurposeOptimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2, is the… read more here.
Keywords: chemotherapy; gastric cancer; ramucirumab; treated fluoropyrimidine ... See more keywords
Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2019.1707211
Abstract: Abstract Objective: This study aimed to compare the cost-effectiveness of ramucirumab versus placebo for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations (AFP) of at least 400 ng/ml in the United States. Methods:… read more here.
Keywords: hepatocellular carcinoma; ramucirumab; cost; cost effectiveness ... See more keywords
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2019.1656715
Abstract: ABSTRACT Introduction: Gastric cancer remains one of the most lethal malignancy, accounting for an estimated 783,000 deaths worldwide in 2018. Although there are several approved drugs for the treatment of gastric cancer, the survival of… read more here.
Keywords: treatment gastric; gastric cancer; ramucirumab; clinical trials ... See more keywords
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy461
Abstract: Abstract Background : Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73–0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined… read more here.
Keywords: mutation status; ramucirumab; ras raf; raf mutation ... See more keywords
Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz247.164
Abstract: Abstract Background Ramucirumab (RAM) with weekly paclitaxel (wPTX) is the recommended standard second-line therapy for advanced and recurrent gastric cancer (GC). In a recent phase II study, wNab-PTX + RAM combination for GC showed promising… read more here.
Keywords: ramucirumab; line therapy; ram; paclitaxel ... See more keywords
The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz434.031
Abstract: Abstract Background Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. To reduce the risk of an infusion-related reaction (IRR) with ramucirumab, H1-antihistamines are recommended as premedication. However, IRR… read more here.
Keywords: without antihistamines; ramucirumab; ramucirumab without; cancer ... See more keywords
Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer
Sign Up to like & getrecommendations! Published in 2020 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000905
Abstract: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer. This is a retrospective study of patients treated with ramucirumab… read more here.
Keywords: response; ramucirumab; gastric cancer; metastatic gastric ... See more keywords
Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/2476469
Abstract: Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic… read more here.
Keywords: ramucirumab; metastatic cancer; double blind; global double ... See more keywords
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Sign Up to like & getrecommendations! Published in 2018 at "Case Reports in Gastroenterology"
DOI: 10.1159/000490906
Abstract: We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously… read more here.
Keywords: junction adenocarcinoma; long term; ramucirumab; gastroesophageal junction ... See more keywords
Angiogenesis-related factors associated with nivolumab efficacy in patients with advanced gastric cancer after refractory or intolerant to ramucirumab-based therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.234
Abstract: 234Background: Nivolumab (Nivo) is a standard therapy after ramucirumab (RAM)-based second-line chemotherapy in patients (pts) with advanced gastric cancer (AGC). However, the relationship between ... read more here.
Keywords: therapy; ramucirumab; gastric cancer; angiogenesis related ... See more keywords
No benefit from ramucirumab in first-line chemotherapy?
Sign Up to like & getrecommendations! Published in 2017 at "Translational gastroenterology and hepatology"
DOI: 10.21037/tgh.2017.03.18
Abstract: Ramucirumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human vascular endothelial growth factor receptor-2 (VEGFR-2). It prevents the binding of VEGFR-2 with its ligands including VEGF-A, VEGF-C, and VEGF-D. Thus, receptor activation… read more here.
Keywords: first line; phase iii; benefit ramucirumab; ramucirumab ... See more keywords